Regulatory and pathogenetic mechanisms of autoantibodies in SLE

Autoimmunity

Volumn 44, Issue 5, 2011, Pages 349-356

  Radic, Marko ^a   Herrmann, Martin ^b   Van Der Vlag, Johan ^c   Rekvig, Ole Petter ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anti DNA antibodies; Apoptosis; Autoantibodies; B cell regulation; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON RECEPTOR; AUTOANTIGEN; B LYMPHOCYTE RECEPTOR; CYCLOPHOSPHAMIDE; DNA ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G2A; INTERLEUKIN 6; LAMININ 1; METHYLPREDNISOLONE; RITUXIMAB; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTICLE; B CELL DEPLETION; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ CD25+ T LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL SELECTION; CELL SURVIVAL; GERMINAL CENTER; GLOMERULONEPHRITIS; HELPER CELL; HUMAN; LIGHT CHAIN; MEMORY CELL; NONHUMAN; PATHOGENICITY; PROTEIN MODIFICATION; REGULATORY MECHANISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; B-LYMPHOCYTES; CELL DEATH; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

EID: 79960134114     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2010.536794     Document Type: Article

References (42)

1. Robbins WC, Holman HR, Deicher H, Kunkel HG. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol Med 1957;96:575-579
2. Ceppellini R, Polli E, Celada F. A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol Med 1957;96:572-574
3. Miescher P. Serology of the L.E. phenomenon.. Hautarzt 1957;8:502-505
4. Radic MZ, Erikson J, Litwin S,WeigertM. B lymphocytes may escape tolerance by revising their antigen receptors. J Exp Med 1993;177:1165-1173 (Pubitemid 23097405)
5. Witsch EJ, Cao H, Fukuyama H, Weigert M. Light chain editing generates polyreactive antibodies in chronic graftversus- host reaction. J Exp Med 2006;203:1761-1772 (Pubitemid 44036281)
6. Tiegs SL, Russell DM, Nemazee D. Receptor editing in selfreactive bone marrow B cells. J Exp Med 1993;177: 1009-1020 (Pubitemid 23097390)
7. Yachimovich N, Mostoslavsky G, Yarkoni Y, Verbovetski I, Eilat D. The efficiency of B cell receptor (BCR) editing is dependent on BCR light chain rearrangement status. Eur J Immunol 2002;32:1164-1174 (Pubitemid 34428834)
8. Yachimovich-Cohen N, Fischel R, Bachar N, Yarkoni Y, Eilat D. Autoimmune NZB/NZWF1 mice utilize B cell receptor editing for generating high-affinity anti-dsDNA autoantibodies from low-affinity precursors. Eur J Immunol 2003;33: 2469-2478 (Pubitemid 37138979)
9. Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, Quinn WJ 3rd, Goenka R, Miller JP, Cho YH, Long V,Ward C, Migone TS, Shlomchik MJ, Cancro MP. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 2008;105: 15517-15522
10. Stadanlick JE, Kaileh M, Karnell FG, Scholz JL, Miller JP, Quinn WJ 3rd, Brezski RJ, Treml LS, Jordan KA, Monroe JG, Sen R, Cancro MP. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 2008;9:1379-1387
11. Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 2006; 176:2703-2710
12. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, Frank D, Rice J, Diamond B, Yu KO, Porcelli S, Davidson A. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116: 724-734 (Pubitemid 43326881)
13. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG? memory B cells. Immunity 2007;26:205-213 (Pubitemid 46329436)
14. Mietzner B, Tsuiji M, Scheid J, Velinzon K, Tiller T, Abraham K, Gonzalez JB, Pascual V, Stichweh D,Wardemann H, Nussenzweig MC. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA 2008;105:9727-9732 (Pubitemid 352031368)
15. Avalos AM, Busconi L, Marshak-Rothstein A. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 2010;43:76-83
16. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 2002;416:603-607 (Pubitemid 34406754)
17. Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P, Richards RJ, Liu CL, Cheung R, Utz PJ, Marshak- Rothstein A, Rifkin IR. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB 2 /2Yaa and FcgammaRIIB 2 /2mouse models of systemic lupus erythematosus. J Immunol 2010;184:796-806
18. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010;6: 280-289
19. Munoz LE, Janko C, Chaurio RA, Schett G, Gaipl US, Herrmann M. IgG opsonized nuclear remnants from dead cells cause systemic inflammation in SLE. Autoimmunity 2010;43:232-235
20. Finke D, Eloranta ML, Ronnblom L. Endogenous type I interferon inducers in autoimmune diseases. Autoimmunity 2009;42:349-352
21. Pisetsky DS, Fairhurst AM. The origin of extracellular DNA during the clearance of dead and dying cells. Autoimmunity 2007;40:281-284 (Pubitemid 46845521)
22. Cline AM, Radic MZ. Murine lupus autoantibodies identify distinct subsets of apoptotic bodies. Autoimmunity 2004;37: 85-93 (Pubitemid 38594272)
23. Reich CF 3rd, Pisetsky DS. The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp Cell Res 2009;315:760-768
24. Fransen JH, Hilbrands LB, Ruben J, Stoffels M, Adema GJ, van der Vlag J, Berden JH. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. Arthritis Rheum 2009;60:2304-2313
25. Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 2010;12: 207
26. van Bavel CC, Dieker J, Muller S, Briand JP, Monestier M, Berden JH, van de Vlag J. Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol Immunol 2009;47:511-516
27. Dieker JW, Fransen JH, Van Bavel CC, Briand JP, Jacobs CW, Muller S, Berden JH, van der Vlag J. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 2007;56:1921-1933 (Pubitemid 47110391)
28. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in neutrophils. J Immunol 2008;180: 1895-1902
29. Schiraldi M, Monestier M. How can a chemical element elicit complex immunopathology? Lessons from mercury-induced autoimmunity. Trends Immunol 2009;30:502-509
30. Zheng Y, JostM, Gaughan JP, Class R, Coyle AJ, MonestierM. ICOS-B7 homologous protein interactions are necessary for mercury-induced autoimmunity. J Immunol 2005;174: 3117-3121 (Pubitemid 40279735)
31. van Bavel CC, Fenton KA, Rekvig OP, van der Vlag J, Berden JH. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2008;58:1892-1899 (Pubitemid 351988079)
32. Mortensen ES, Rekvig OP. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 2009;20:696-704
33. Fenton K, Tommeras B, Marion TN, Rekvig OP. Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity 2010;43:179-188
34. Fenton K, Fismen S, Hedberg A, Seredkina N, Fenton C, Mortensen ES, Rekvig OP. Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PLoS One 2009;4:e8474
35. Liang Z, Chang S, Youn MS, Mohan C. Molecular hallmarks of anti-chromatin antibodies associated with the lupus susceptibility locus, Sle1. Mol Immunol 2009;46:2671-2681
36. Vuyyuru R, Mohan C, Manser T, Rahman ZS. The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol 2009;183:5716-5727
37. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum 2009;61:482-487
38. Manson JJ, Ma A, Rogers P, Mason LJ, Berden JH, van der Vlag J, D'Cruz DP, Isenberg DA, Rahman A. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: A prospective longitudinal study. Arthritis Res Ther 2009;11:R154
39. Amital H, Heilweil-Harel M, Ulmansky R, Harlev M, Toubi E, Hershko A, Naparstek Y. Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption. Rheumatology (Oxford) 2007;46:1433-1437 (Pubitemid 47317089)
40. Yin H, BorghiMO, Delgado-Vega AM, Tincani A, Meroni PL, Alarcon-Riquelme ME. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Rheum 2009;60:2468-2471
41. Fredi M, Tincani A, Yin H, Delgado-Vega AM, Borghi MO, Meroni PL, Alarcon-Riquelme ME. IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis Rheum 2010;62:1201-1202
42. Munoz LE, van Bavel CC, Franz S, Berden JH, Herrmann M, van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008;17:371-375 (Pubitemid 351798710)